Skip to main content
OpenTrials
Completed

NCT Number: NCT00215436

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

The purpose of this study is to determine the safety and efficacy of the investigational drug in comparison with a placebo.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Jasper, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Medical diagnosis of COPD
  • Current or prior history of cigarette smoking

Exclusion criteria

  • Medical diagnosis of asthma
  • Chest X-ray diagnostic of significant disease other than COPD
  • Significant condition or disease other than COPD

Treatment and study plan

formoterol fumarate

Drug

Primary outcomes

  1. Measure of lung function

Secondary outcomes

  1. Change in lung function, as well as vital signs

  2. Physical Exam results, Adverse event reporting, etc

Sponsors and collaborators

Lead sponsor

Dey

Industry

Registry information

Official study title

A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Important dates

Study start
2005
Primary completion
2005
Study completion
2006
First posted
Sep 22, 2005
Registry last updated
Nov 10, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.